Observational Study to Assess Safety and Effectiveness of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 14 Jan 2025 Planned number of patients changed from 90 to 110.
- 20 Feb 2024 New trial record
- 19 Feb 2024 Status changed from not yet recruiting to recruiting.